EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mesonephric‐type adenocarcinomas of the ovary: prevalence, diagnostic reproducibility, outcome, and value of PAX2

Martin Köbel iD, Eun Young Kang, Sandra Lee, Travis Ogilvie, Tatjana Terzic, Linyuan Wang, Nicholas Jp Wiebe, Zainab Al-Shamma, Linda S Cook, Gregg S Nelson, Colin Jr Stewart, Andreas von Deimling und 2 weitere

The Journal of Pathology: Clinical Research · 2024

DOI: 10.1002/2056-4538.12389 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, 2024. Verfasst von Martin Köbel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Calgary, Calgary, AB, Canada. Hauptthemen laut MEDLINE: Ovarian Neoplasms, PAX2 Transcription Factor, Biomarkers, Tumor. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alberta Precision Laboratories.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mesonephric‐type (or ‐like) adenocarcinomas (MAs) of the ovary are an uncommon and aggressive histotype. They appear to arise through transdifferentiation from Müllerian lesions creating diagnostic challenges. Thus, we aimed to develop a histologic and immunohistochemical (IHC) approach to optimize the identification of MA over its histologic mimics, such as ovarian endometrioid carcinoma (EC). First, we screened 1,537 ovarian epithelial neoplasms with a four‐marker IHC panel of GATA3, TTF1, ER, and PR followed by a morphological review of EC to identify MA in retrospective cohorts. Interobserver reproducibility for the distinction of MA versus EC was assessed in 66 cases initially without and subsequently with IHC information (four‐marker panel). Expression of PAX2, CD10, and calretinin was evaluated separately, and survival analyses were performed. We identified 23 MAs from which 22 were among 385 cases initially reported as EC (5.7%) and 1 as clear cell carcinoma. The interobserver reproducibility increased from fair to substantial ( κ = 0.376–0.727) with the integration of the four‐marker IHC panel. PAX2 was the single most sensitive and specific marker to distinguish MA from EC and could be used as a first‐line marker together with ER/PR and GATA3/TTF1. Patients with MA had significantly increased risk of earlier death from disease (hazard ratio = 3.08; 95% CI, 1.62–5.85; p < 0.0001) compared with patients with EC, when adjusted for age, stage, and p53 status. A diagnosis of MA has prognostic implications for stage I disease, and due to the subtlety of morphological features in some tumors, a low threshold for ancillary testing is recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsPAX2 Transcription FactorBiomarkers, TumorHumansFemaleMiddle AgedReproducibility of ResultsAgedAdultRetrospective StudiesPrevalenceImmunohistochemistryAdenocarcinomaDiagnosis, DifferentialObserver VariationAged, 80 and overCarcinoma, Endometrioid

Stichwörter der Autor:innen

GATA3PAX2TTF1mesonephricmesonephric‐like

Substanzen

PAX2 Transcription FactorBiomarkers, TumorPAX2 protein, human

Autor:innen und Institutionen

  • Department of Pathology, University of Calgary, Calgary, AB, Canada.
  • Department of CSPH-Epidemiology, University of Colorado-Anschutz, Aurora, CO, USA.
  • Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
  • Department of Anatomical Pathology, King Edward Memorial Hospital, Subiaco, WA, Australia.
  • School for Women's and Infants' Health, University of Western Australia, Perth, WA, Australia.
  • Department of Neuropathology, Heidelberg University Hospital and CCU Neuropathology DKFZ, Heidelberg, Germany.

ORCID-Profile: Martin Köbel, Felix Kf Kommoss

Förderung

  • Alberta Precision Laboratories

Zitieren

APA

Köbel, M., Kang, E. Y., Lee, S., Ogilvie, T., Terzic, T., Wang, L., Wiebe, N. J., Al-Shamma, Z., Cook, L. S., Nelson, G. S., Stewart, C. J., von Deimling, A., Kommoss, F. K., & Lee, C. H. (2024). Mesonephric‐type adenocarcinomas of the ovary: prevalence, diagnostic reproducibility, outcome, and value of PAX2. The Journal of Pathology: Clinical Research. https://doi.org/10.1002/2056-4538.12389

Vancouver

Köbel M, Kang EY, Lee S, Ogilvie T, Terzic T, Wang L, et al. Mesonephric‐type adenocarcinomas of the ovary: prevalence, diagnostic reproducibility, outcome, and value of PAX2. The Journal of Pathology: Clinical Research. 2024. doi:10.1002/2056-4538.12389

BibTeX
@article{Kbel2024,
  author = {Köbel, Martin and Kang, Eun Young and Lee, Sandra and Ogilvie, Travis and Terzic, Tatjana and Wang, Linyuan and Wiebe, Nicholas Jp and Al-Shamma, Zainab and Cook, Linda S and Nelson, Gregg S and Stewart, Colin Jr and von Deimling, Andreas and Kommoss, Felix Kf and Lee, Cheng-Han},
  title = {Mesonephric‐type adenocarcinomas of the ovary: prevalence, diagnostic reproducibility, outcome, and value of PAX2},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2024},
  doi = {10.1002/2056-4538.12389}
}
Kostenlos starten →